CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Adaptimmune Therapeutics PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Adaptimmune Therapeutics PLC - ADR
60 Jubilee Avenue, Milton Park
Phone: +44 1235430000p:+44 1235430000 ABINGDON, OX14 4RX  United Kingdom Ticker: ADAPADAP

Business Summary
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202412/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board David M.Mott 58 1/1/2017 9/1/2014
Chief Executive Officer, Director AdrianRawcliffe 51 9/1/2019 3/1/2015
Chief Financial Officer Gavin H.Wood 54 4/1/2020 4/1/2020
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
TCR2 Therapeutics Inc. 100 Binney St CAMBRIDGE MA United States
Adaptimmune LLC 351 Rouse Boulevard Philadalphia PA United States

Business Names
Business Name
ADAP
Adaptimmune B.V.
Adaptimmune Limited
7 additional Business Names available in full report.

General Information
Number of Employees: 449 (As of 12/31/2023)
Outstanding Shares: 1,533,371,874 (As of 5/13/2024)
Shareholders: 27
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, June 14, 2024